Alternate Day Fasting for Weight Loss in Obese Subjects

This study has been completed.
Sponsor:
Information provided by:
University of Illinois at Chicago
ClinicalTrials.gov Identifier:
NCT00960505
First received: August 14, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted
  Purpose

Background:

The ability of modified alternate day fasting (ADF) (i.e. consuming 25% of energy needs on the fast day, ad libitum fed on feed day) to facilitate weight loss and lower vascular disease risk in obese individuals remains unknown. Objective:

This study examined the effects of ADF, administered under controlled versus self-implemented conditions, on body weight and coronary heart disease (CHD) risk indicators in obese adults.

Design:

Sixteen obese subjects (12 women/4 men) completed a 10-week trial, consisting of 3 phases: 1) 2-week control phase, 2) 4-week weight loss/ADF controlled feeding phase, and 3) 4-week weight loss/ADF self-selected feeding phase.


Condition Intervention Phase
Obesity
Coronary Heart Disease
Other: Diet
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Alternate Day Fasting for Weight Loss and Cardioprotection in Obese Adults

Resource links provided by NLM:


Further study details as provided by University of Illinois at Chicago:

Primary Outcome Measures:
  • Body weight [ Time Frame: Weekly ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Adipokine concentrations [ Time Frame: 4-week intervals ] [ Designated as safety issue: No ]
  • Cholesterol concentrations [ Time Frame: 4-week intervals ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: April 2009
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Alternate day fasting
Alternate day fasting regimen administered for 8 weeks
Other: Diet
Alternate day fasting

  Eligibility

Ages Eligible for Study:   35 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 35 to 65 years
  • Body mass index between 30 and 39.9 kg/m2
  • Weight stable for 3 months prior to the beginning of the study (i.e. less than 5 kg weight loss or weight gain)
  • Non-diabetic
  • No history of cardiovascular disease
  • Lightly active (i.e. <3 h/week of light intensity exercise at 2.5 to 4.0 metabolic equivalents (METs) for 3 months prior to the study (10)
  • Non-smoker
  • Not taking weight loss, lipid or glucose lowering medications.

Exclusion Criteria:

  • Peri-menopausal women were excluded from the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00960505

Locations
United States, Illinois
University of Illinois, Chicago
Chicago, Illinois, United States, 60622
Sponsors and Collaborators
University of Illinois at Chicago
  More Information

No publications provided

Responsible Party: Krista Varady, PhD, University of Illinois, Chicago
ClinicalTrials.gov Identifier: NCT00960505     History of Changes
Other Study ID Numbers: UIC-004-2009
Study First Received: August 14, 2009
Last Updated: August 14, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by University of Illinois at Chicago:
coronary heart disease risk

Additional relevant MeSH terms:
Heart Diseases
Weight Loss
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Cardiovascular Diseases
Body Weight Changes
Body Weight
Signs and Symptoms
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on September 15, 2014